Evidence map›Paper›PMID 25287070›Full record

ReviewThe pharmacogenomics journal2015

An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.

N A Meadows, A Morrison, D A Brindley, A Schuh, R W Barker

Abstract readReview
PubMed Publisher
In one paragraph

Review in The pharmacogenomics journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

N A MeadowsKinapse, Wimbledon, London, UK.
A MorrisonAmgen, Cambridge, UK.
D A Brindley1] Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK [2] Harvard Stem Cell Institute, Holyoke Centre, Cambridge, MA, USA [3] UCL Centre for Behavioural Medicine, UCL School of Pharmacy, BMA House, London, UK [4] Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK and University College London, London, UK.
A SchuhOxford National Institute of Health Research (NIHR), Biomedical Research Centre (BRC), Molecular Diagnostic Centre (MDC), Oxford University Hospitals, Oxford, UK.
R W BarkerOxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK and University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, a range of products based on genomics, proteomics and metabolomics have facilitated the development of 'stratified' medicines and companion diagnostics. This investigation profiles a series of targeted medicines and corresponding diagnostics, and their role(s) in supporting evidence-based medicine. Despite their potential benefits we found that scientific, financial and regulatory barriers impede the development and adoption of companion diagnostics. Therefore, in order to realise improvements to the risk/benefit profiles of health-care interventions-notably reducing clinical uncertainty-conferred by the use of companion diagnostics, industry representatives, health-care providers and regulators will need a coordinated response to overcome these barriers.

Indexed as

Clinical Trials, Phase III as TopicDrug DiscoveryDrug IndustryHumansPrecision Medicine

Identifiers

PMID25287070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.